The Effect of Etrasimod on Fecal Calprotectin and High-sensitivity C-reactive Protein: Results From the ELEVATE UC Clinical Program
Inflammatory Bowel Diseases · 10.04.2025 · 31 (4) · 923-934
DOI: 10.1093/ibd/izae111 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 20.06.2024. Verfasst von Vipul Jairath und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada. Hauptthemen laut MEDLINE: Leukocyte L1 Antigen Complex, Feces, C-Reactive Protein, Colitis, Ulcerative. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pfizer.
Abstract (Originalsprache)
Background
Biomarkers offer potential alternatives to endoscopies in monitoring ulcerative colitis (UC) progression and therapeutic response. This post hoc analysis of the ELEVATE UC clinical program assessed potential predictive values of fecal calprotectin (fCAL) and high-sensitivity C-reactive protein (hsCRP) as biomarkers and associated responses to etrasimod, an oral, once-daily, selective sphingosine 1-phosphate (S1P)1,4,5 receptor modulator for the treatment of moderately to severely active UC, in 2 phase 3 clinical trials.
Methods
In ELEVATE UC 52 and ELEVATE UC 12, patients were randomized 2:1 to 2 mg of etrasimod once daily or placebo for 52 or 12 weeks, respectively. Fecal calprotectin/hsCRP differences between responders and nonresponders for efficacy end points (clinical remission, clinical response, endoscopic improvement-histologic remission [EIHR]) were assessed by Wilcoxon P-values. Sensitivity and specificity were presented as receiver operating characteristics (ROC) curves with area under the curve (AUC).
Results
In ELEVATE UC 52 and ELEVATE UC 12, 289 and 238 patients received etrasimod and 144 and 116 received placebo, respectively. Baseline fCAL/hsCRP concentrations were generally balanced. Both trials had lower week-12 median fCAL levels in week-12 responders vs nonresponders receiving etrasimod for clinical remission, clinical response, and EIHR (all P < .001), with similar trends for hsCRP levels (all P < .01). For etrasimod, AUCs for fCAL/hsCRP and EIHR were 0.85/0.74 (week 12; ELEVATE UC 52), 0.83/0.69 (week 52; ELEVATE UC 52), and 0.80/0.65 (week 12; ELEVATE UC 12).
Conclusions
Fecal calprotectin/hsCRP levels decreased with etrasimod treatment; ROC analyses indicated a prognostic correlation between fCAL changes during induction and short-/long-term treatment response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine and Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada.
- University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, IL, USA.
- Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
- Department of Chronic Diseases and Metabolism, Translational Research in Gastrointestinal Disorders, KU Leuven, Leuven, Belgium.
- Department of Gastroenterology, University of Health Sciences, Antalya Training and Research Hospital, Antalya, Turkey.
- Division of Gastroenterology, Crohn's and Colitis Center, University of Miami Miller School of Medicine, Miami, FL, USA.
ORCID-Profile: Vipul Jairath, Bram Verstockt, Maria T Abreu, Marc Fellmann, Britta Siegmund
Förderung
- Pfizer
Zitieren
APA
Jairath, V., Rubin, D. T., Verstockt, B., Çekin, A. H., Abreu, M. T., Lees, C. W., Fellmann, M., Woolcott, J. C., Crosby, C., Wu, J., Bhattacharjee, A., Herman, D., Gu, G., & Siegmund, B. (2025). The Effect of Etrasimod on Fecal Calprotectin and High-sensitivity C-reactive Protein: Results From the ELEVATE UC Clinical Program. Inflammatory Bowel Diseases, 31(4), 923-934. https://doi.org/10.1093/ibd/izae111
Vancouver
Jairath V, Rubin DT, Verstockt B, Çekin AH, Abreu MT, Lees CW, et al. The Effect of Etrasimod on Fecal Calprotectin and High-sensitivity C-reactive Protein: Results From the ELEVATE UC Clinical Program. Inflammatory Bowel Diseases. 2025;31(4):923-934. doi:10.1093/ibd/izae111
BibTeX
@article{Jairath2025,
author = {Jairath, Vipul and Rubin, David T and Verstockt, Bram and Çekin, Ayhan H and Abreu, Maria T and Lees, Charlie W and Fellmann, Marc and Woolcott, John C and Crosby, Catherine and Wu, Joseph and Bhattacharjee, Abhishek and Herman, David and Gu, Guibao and Siegmund, Britta},
title = {The Effect of Etrasimod on Fecal Calprotectin and High-sensitivity C-reactive Protein: Results From the ELEVATE UC Clinical Program},
journal = {Inflammatory Bowel Diseases},
year = {2025},
volume = {31},
number = {4},
pages = {923--934},
doi = {10.1093/ibd/izae111}
}
EUVIMED